Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study

The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections

Niccolò Buetti et al. Intensive Care Med. 2024 Jun.

Erratum in

  • Correction: The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections.
    Buetti N, Tabah A, Setti N, Ruckly S, Barbier F, Akova M, Aslan AT, Leone M, Bassetti M, Morris AC, Arvaniti K, Paiva JA, Ferrer R, Qiu H, Montrucchio G, Cortegiani A, Kayaaslan B, De Bus L, De Waele JJ, Timsit JF; EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP), and the OUTCOMEREA Network. Buetti N, et al. Intensive Care Med. 2024 Jun;50(6):1017-1018. doi: 10.1007/s00134-024-07415-6. Intensive Care Med. 2024. PMID: 38587556 Free PMC article. No abstract available.

Abstract

Purpose: The primary objective of this study was to evaluate the associations between centre/country-based factors and two important process and outcome indicators in patients with hospital-acquired bloodstream infections (HABSI).

Methods: We used data on HABSI from the prospective EUROBACT-2 study to evaluate the associations between centre/country factors on a process or an outcome indicator: adequacy of antimicrobial therapy within the first 24 h or 28-day mortality, respectively. Mixed logistical models with clustering by centre identified factors associated with both indicators.

Results: Two thousand two hundred nine patients from two hundred one intensive care units (ICUs) were included in forty-seven countries. Overall, 51% (n = 1128) of patients received an adequate antimicrobial therapy and the 28-day mortality was 38% (n = 839). The availability of therapeutic drug monitoring (TDM) for aminoglycosides everyday [odds ratio (OR) 1.48, 95% confidence interval (CI) 1.03-2.14] or within a few hours (OR 1.79, 95% CI 1.34-2.38), surveillance cultures for multidrug-resistant organism carriage performed weekly (OR 1.45, 95% CI 1.09-1.93), and increasing Human Development Index (HDI) values were associated with adequate antimicrobial therapy. The presence of intermediate care beds (OR 0.63, 95% CI 0.47-0.84), TDM for aminoglycoside available everyday (OR 0.66, 95% CI 0.44-1.00) or within a few hours (OR 0.51, 95% CI 0.37-0.70), 24/7 consultation of clinical pharmacists (OR 0.67, 95% CI 0.47-0.95), percentage of vancomycin-resistant enterococci (VRE) between 10% and 25% in the ICU (OR 1.67, 95% CI 1.00-2.80), and decreasing HDI values were associated with 28-day mortality.

Conclusion: Centre/country factors should be targeted for future interventions to improve management strategies and outcome of HABSI in ICU patients.

Keywords: Bacteraemia; Centre; Hospital-acquired bloodstream infections; Outcome indicator; Process indicator.

PubMed Disclaimer

Conflict of interest statement

NB received a Mobility grant from the Swiss National Science Foundation (Grant number: P400PM_183865). JJDW is a senior clinical investigator funded by the Research Foundation Flanders (FWO, Ref. 1881020N). ACM is supported by a Medical Research Council Clinician Scientist Fellowship (MR/V006118/1) and received speaking fees from Fischer & Paykel, Biomerieux; he participated in scientific advisory board of Cambridge infection diagnostics; he received support for the present manuscript by the medical research council (Clinician Scientist Fellowship grant number: MR/V006118/1). ML received consulting fees from LFB, Shionogi, AOP Pharma and Viatris outside of this project. RF has received consulting fees from Inotrem, Pfizer and Cytosorbent and honoraria for lectures from Shionogi, MSD, Menarini, Thermofisher and Gilead. GM received payment for honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Thermofisher, Gilead, Pfizer and 3 M; and she participated on a data Safety Monitoring Board or Advisory Board by Gilead and 3 M. AC received fees for lectures and scientific consultancies by Gilead, MSD, Mundipharma, Pfizer. LDB participated on data safety monitoring or advisory board of MSD. MB received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Angelini, Biomerieux, Cidara, Gilead, Menarini, MSD, Pfizer, and Shionogi. MB participated on data safety monitoring board or advisory board of Angelini, Biomerieux, Cidara, Gilead, Menarini, MSD, Pfizer, and Shionogi. MA participated on a data safety board for GSK and is the president of the International Immunocompromised Host Society.

Figures

Fig. 1
Fig. 1
Multivariable mixed logistical models for adequate antimicrobial therapy within the first 24 h and 28-day mortality. The first panel relates to adequate antimicrobial therapy within the first 24 h, the second panel 28-day mortality. ICU intensive care unit, OR odds ratio, CI confidence interval, TDM therapeutic drug monitoring, AMR antimicrobial resistance
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducomble T, et al. Burden of six healthcare-associated infections on european population health: estimating incidence-based disability-adjusted life years through a population prevalence-based modelling study. PLoS Med. 2016;13(10):e1002150. doi: 10.1371/journal.pmed.1002150. - DOI - PMC - PubMed
    1. Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill Bull Eur Malad Transm Eur Commun Dis Bull. 2018;23(16). - PMC - PubMed
    1. Niederman MS, Baron RM, Bouadma L, Calandra T, Daneman N, DeWaele J, et al. Initial antimicrobial management of sepsis. Crit Care. 2021;25(1):307. doi: 10.1186/s13054-021-03736-w. - DOI - PMC - PubMed
    1. Ten Oever J, Jansen JL, van der Vaart TW, Schouten JA, Hulscher M, Verbon A. Development of quality indicators for the management of Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2019;74(11):3344–3351. doi: 10.1093/jac/dkz342. - DOI - PMC - PubMed
    1. Klompas M, Rhee C, Singer M. The importance of shifting sepsis quality measures from processes to outcomes. JAMA. 2023;329(7):535–536. doi: 10.1001/jama.2023.0340. - DOI - PubMed

Publication types

Substances

LinkOut - more resources